Pomdoctor Limited (NASDAQ: POM) Stock Competitors & Peer Comparison

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, RPRX has a market cap of 29.6B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while RPRX trades at $66.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas RPRX's P/E ratio is 12.67. In terms of profitability, POM's ROE is +0.80%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, POM is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check RPRX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas WBA's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.80%, compared to WBA's ROE of -0.57%. Regarding short-term risk, POM is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for POM.Check WBA's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CORT has a market cap of 8.7B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CORT trades at $80.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CORT's P/E ratio is 229.89. In terms of profitability, POM's ROE is +0.80%, compared to CORT's ROE of +0.08%. Regarding short-term risk, POM is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for POM.Check CORT's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, KNSA has a market cap of 7.1B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while KNSA trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas KNSA's P/E ratio is 69.77. In terms of profitability, POM's ROE is +0.80%, compared to KNSA's ROE of +0.17%. Regarding short-term risk, POM is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for POM.Check KNSA's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while LQDA trades at $41.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas LQDA's P/E ratio is 30.55. In terms of profitability, POM's ROE is +0.80%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, POM is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for POM.Check LQDA's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while PBH trades at $49.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas PBH's P/E ratio is 11.26. In terms of profitability, POM's ROE is +0.80%, compared to PBH's ROE of +0.09%. Regarding short-term risk, POM is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for POM.Check PBH's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas HROWL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, POM is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWL's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas HROWM's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, POM is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWM's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, LTGO has a market cap of 811.5M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while LTGO trades at $13.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas LTGO's P/E ratio is -5.35. In terms of profitability, POM's ROE is +0.80%, compared to LTGO's ROE of N/A. Regarding short-term risk, POM is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for POM.Check LTGO's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, HELP has a market cap of 545.5M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while HELP trades at $8.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas HELP's P/E ratio is -2.11. In terms of profitability, POM's ROE is +0.80%, compared to HELP's ROE of -0.71%. Regarding short-term risk, POM is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for POM.Check HELP's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas SVA's P/E ratio is -5.68. In terms of profitability, POM's ROE is +0.80%, compared to SVA's ROE of -0.01%. Regarding short-term risk, POM is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for POM.Check SVA's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CUVL has a market cap of 249.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CUVL trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CUVL's P/E ratio is 10.68. In terms of profitability, POM's ROE is +0.80%, compared to CUVL's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for POM.Check CUVL's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, HITI has a market cap of 230.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while HITI trades at $2.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas HITI's P/E ratio is -9.57. In terms of profitability, POM's ROE is +0.80%, compared to HITI's ROE of -0.36%. Regarding short-term risk, POM is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for POM.Check HITI's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CELG-RI has a market cap of 194.1M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CELG-RI trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, POM is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for POM.Check CELG-RI's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ETRA has a market cap of 155.1M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ETRA trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ETRA's P/E ratio is -2.76. In terms of profitability, POM's ROE is +0.80%, compared to ETRA's ROE of N/A. Regarding short-term risk, POM is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for POM.Check ETRA's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, TRXB has a market cap of 114.4M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while TRXB trades at $13.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas TRXB's P/E ratio is -5.56. In terms of profitability, POM's ROE is +0.80%, compared to TRXB's ROE of N/A. Regarding short-term risk, POM is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for POM.Check TRXB's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ATLN's P/E ratio is -0.68. In terms of profitability, POM's ROE is +0.80%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, POM is more volatile compared to ATLN. This indicates higher risk in terms of short-term price fluctuations for POM.Check ATLN's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CTOR has a market cap of 55.2M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CTOR trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CTOR's P/E ratio is -1.26. In terms of profitability, POM's ROE is +0.80%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, POM is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for POM.Check CTOR's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, RTSN has a market cap of 43.6M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while RTSN trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas RTSN's P/E ratio is -4.45. In terms of profitability, POM's ROE is +0.80%, compared to RTSN's ROE of N/A. Regarding short-term risk, POM is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for POM.Check RTSN's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas RAD's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.80%, compared to RAD's ROE of +2.76%. Regarding short-term risk, POM is more volatile compared to RAD. This indicates higher risk in terms of short-term price fluctuations for POM.Check RAD's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas GLTO's P/E ratio is -1.78. In terms of profitability, POM's ROE is +0.80%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, POM is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for POM.Check GLTO's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while COSM trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas COSM's P/E ratio is -0.42. In terms of profitability, POM's ROE is +0.80%, compared to COSM's ROE of -1.19%. Regarding short-term risk, POM is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for POM.Check COSM's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, NSRX has a market cap of 27.6M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while NSRX trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas NSRX's P/E ratio is -4.44. In terms of profitability, POM's ROE is +0.80%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, POM is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check NSRX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, SCYX has a market cap of 24M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while SCYX trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas SCYX's P/E ratio is -1.11. In terms of profitability, POM's ROE is +0.80%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, POM is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for POM.Check SCYX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while BFRI trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas BFRI's P/E ratio is -1.59. In terms of profitability, POM's ROE is +0.80%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, POM is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for POM.Check BFRI's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CNSY has a market cap of 12.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CNSY trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CNSY's P/E ratio is -0.41. In terms of profitability, POM's ROE is +0.80%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, POM is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for POM.Check CNSY's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while AZR trades at $3.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas AZR's P/E ratio is -0.24. In terms of profitability, POM's ROE is +0.80%, compared to AZR's ROE of N/A. Regarding short-term risk, POM is more volatile compared to AZR. This indicates higher risk in terms of short-term price fluctuations for POM.Check AZR's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CJJD's P/E ratio is -0.46. In terms of profitability, POM's ROE is +0.80%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, POM is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CJJD's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas SSY's P/E ratio is -2.86. In terms of profitability, POM's ROE is +0.80%, compared to SSY's ROE of -0.09%. Regarding short-term risk, POM is more volatile compared to SSY. This indicates higher risk in terms of short-term price fluctuations for POM.Check SSY's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while SCNX trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas SCNX's P/E ratio is -1.54. In terms of profitability, POM's ROE is +0.80%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, POM is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for POM.Check SCNX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while BGMS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas BGMS's P/E ratio is -0.25. In terms of profitability, POM's ROE is +0.80%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, POM is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for POM.Check BGMS's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas MDVL's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.80%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, POM is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for POM.Check MDVL's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, EOCN has a market cap of 2.8M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while EOCN trades at $2.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas EOCN's P/E ratio is -0.19. In terms of profitability, POM's ROE is +0.80%, compared to EOCN's ROE of N/A. Regarding short-term risk, POM is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for POM.Check EOCN's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, PAVS has a market cap of 2.7M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while PAVS trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas PAVS's P/E ratio is -0.03. In terms of profitability, POM's ROE is +0.80%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, POM is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for POM.Check PAVS's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ATNFW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, POM is more volatile compared to ATNFW. This indicates higher risk in terms of short-term price fluctuations for POM.Check ATNFW's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, POM's ROE is +0.80%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, POM is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for POM.Check BGMSP's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas AZNH's P/E ratio is 38.35. In terms of profitability, POM's ROE is +0.80%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for POM.Check AZNH's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ASBP has a market cap of 842.2K. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ASBP trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ASBP's P/E ratio is -0.31. In terms of profitability, POM's ROE is +0.80%, compared to ASBP's ROE of +19.93%. Regarding short-term risk, POM is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for POM.Check ASBP's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while BFRIW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas BFRIW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, POM is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for POM.Check BFRIW's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, POM's ROE is +0.80%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, POM is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for POM.Check LFLYW's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ASBPW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ASBPW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, POM is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for POM.Check ASBPW's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, PRPH has a market cap of 91.1K. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas PRPH's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, POM is more volatile compared to PRPH. This indicates higher risk in terms of short-term price fluctuations for POM.Check PRPH's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, OREX has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas OREX's P/E ratio is -0.14. In terms of profitability, POM's ROE is +0.80%, compared to OREX's ROE of -0.54%. Regarding short-term risk, POM is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for POM.Check OREX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas SHPG's P/E ratio is 11.35. In terms of profitability, POM's ROE is +0.80%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, POM is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for POM.Check SHPG's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas POZN's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to POZN's ROE of +0.61%. Regarding short-term risk, POM is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for POM.Check POZN's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas ESRX's P/E ratio is 10.69. In terms of profitability, POM's ROE is +0.80%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, POM is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check ESRX's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas IPXL's P/E ratio is -10.11. In terms of profitability, POM's ROE is +0.80%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, POM is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for POM.Check IPXL's competition here

Pomdoctor Limited (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 16.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, POM is priced at $1.91 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -0.28, whereas CPD's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.80%, compared to CPD's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CPD's competition here